Osimertinib was approved for metastatic NSCLC patients whose tumors harbor the T790M EGFR mutation following progression on EGFR-TKI therapy in 2015 (AstraZeneca Pharmaceuticals LP, 2015b; Kuiper et al., 2014). This evidence concerns the gene EGFR and non-small cell lung carcinoma.